Telogen effluvium: a sequela of COVID‐19

Mieczkowska, Karolina; Deutsch, Adam; Borok, Jenna; Guzman, Anthony K.; Fruchter, Renee; Patel, Parth; Wind, Olivia H.; McLellan, Beth N.; Mann, Ranon E.; Halverstam, Caroline

doi:10.1111/ijd.15313

Cited by 79 publications

(88 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, to our knowledge, the only other studies investigating TE triggered by COVID‐19 infection are case reports and one 10‐patient case series 8,9 . The case series published by Mieczkowska et al included four White patients, one Black patient, and four patients of unknown race 8 . Compared with other studies, we had significantly more skin of color patients, as our case series included six Black patients and one Middle Eastern patient.…”

Section: Discussionmentioning

confidence: 77%

“…This was a single health system, retrospective study with a relatively small sample size. However, to our knowledge, the only other studies investigating TE triggered by COVID‐19 infection are case reports and one 10‐patient case series 8,9 . The case series published by Mieczkowska et al included four White patients, one Black patient, and four patients of unknown race 8 .…”

Section: Discussionmentioning

confidence: 99%

“…However, to our knowledge, the only other studies investigating TE triggered by COVID-19 infection are case reports and one 10-patient case series. 8,9 The case series published by Mieczkowska In addition, TE caused by hydroxychloroquine, azithromycin, or other medications cannot be ruled out. The global pandemic itself is another potential source of psychosocial stress, and there may be an overall increase in the incidence of TE as a result.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Telogen effluvium associated with COVID‐19 infection

Olds

Liu

Luk

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Telogen effluvium (TE) is characterized by diffuse hair shedding 2‐3 months after a stressor, and COVID‐19 infection is potentially one such stressor. Those who were infected with the virus were under immense psychosocial and physiologic stress. We retrospectively reviewed electronic medical records of 552 patients who were evaluated by a Henry Ford Health System dermatologist between February 2020 and September 2020 and had a diagnosis of COVID‐19 infection. Ten patients were identified with TE attributed to COVID‐19 infection and described their presentations as a case series. For the ten patients selected, the mean age was 48.5 years old and 90% were female. Six of the patients were Black, one Middle Eastern, and three White. On average, the hair shedding began 50 days after the first symptom of COVID‐19 infection. About 80% of these patients were treated with antibiotics, systemic corticosteroids, and/or hydroxychloroquine for their COVID‐19 infection and 70% were hospitalized. The presentations of these patients suggest that COVID‐19 infection may be a significant trigger of TE. TE caused by hydroxychloroquine, azithromycin or other medications cannot be ruled out, and the global pandemic itself is a source of psychosocial stress. Further studies will be needed to understand the long‐term prevalence and prognosis of TE associated with COVID‐19 infection.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Telogen effluvium associated with COVID‐19 infection

Olds

Liu

Luk

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Hair loss after COVID-19 could be considered as telogen effluvium, defined by diffuse hair loss after an important systemic stressor or infection, and it is caused because of premature follicular transitions from active growth phase (anagen) to resting phase (telogen). It is a self-limiting condition that lasts approximately 3 months, but it could cause emotional distress 28 . Dyspnea and cough were found in 24% and 19% of patients, respectively (Table 2, Figure 2).…”

Section: Discussionmentioning

confidence: 99%

More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis

López-Léon

Wegman-Ostrosky

Perelman

et al. 2021

Preprint

237

160

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1st of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I2 statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.

show abstract

“…Hair loss after COVID-19 could be considered as telogen e uvium, de ned by diffuse hair loss after an important systemic stressor or infection, and it is caused because of premature follicular transitions from active growth phase (anagen) to resting phase (telogen). It is a self-limiting condition that lasts approximately 3 months, but it could cause emotional distress (28).…”

Section: Discussionmentioning

confidence: 99%

More than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis

López-Léon

Wegman-Ostrosky²,

Perelman³

et al. 2021

SSRN Journal

View full text Add to dashboard Cite

Background. COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing longterm effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. Methods. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1 st of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I 2 statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Metaanalysis (PRISMA) guidelines, although the study protocol was not registered. Results. A total of 18,251 publications were identi ed, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The ve most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). Conclusions. In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, the severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multidisciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care. Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in China in December 2019. Since then, more than 90 million people worldwide have been infected after a year, and over 2 million people have died from the coronavirus disease 2019 (COVID-19)(1). Although unprecedented efforts from the scienti c and medical community have been directed to sequence, diagnose, treat, and prevent COVID-19, individuals' lasting effects after the acute phase of the disease are yet to be revealed. To date, there is no established term to coin the slow and persistent condition in individuals with lasting sequelae of COVID-19. Different authors have used the terms "Long-COVID-19", "Long Haulers", "Post-acute COVID-19", "Persistent COVID-19 Symptoms", "Post COVID-19 manifestations", "Longterm COVID-19 effects", "Post COVID-19 syndrome", amon...

show abstract

Telogen effluvium: a sequela of COVID‐19

Cited by 79 publications

References 6 publications

Telogen effluvium associated with COVID‐19 infection

Telogen effluvium associated with COVID‐19 infection

More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis

More than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About